Banque Populaire Rives de Paris
VC Fund
Paris, France
Banque Populaire Rives de Paris is a VC fund in Paris focused on Laser and Beauty. Banque Populaire Rives de Paris operates as a regional and co-operative bank.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Banque Populaire Rives de Paris invests in
Stages Banque Populaire Rives de Paris invests in
Countries Banque Populaire Rives de Paris invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $1.6M–$1.6M
Investment Focus
Industry
- Laser 1 (25%)
- Beauty 1 (25%)
- Fitness 1 (25%)
- Medical 1 (25%)
- Wellness 1 (25%)
Stage
- Seed 2 (50%)
- Series A 1 (25%)
- Post-IPO Debt 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Arnaud Paquier
Corporate Business Center Director
|
Corporate Business Center Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Up&Charge
|
Up&Charge is an automated induction charging station that provides wireless electric charging solution through induction and remote activation on the application for electric vehicles. | $1.6M / Seed / Jul 24, 2024 | |
Ray studios
|
Ray Studios is a Tattoo removal studio that employs hydraulic acoustic wave technology in its "Le Ray Spark" Tattoo removal treatment device. | $3.2M / Series A / Jun 13, 2024 | |
Groupe Flo
|
Groupe Flo is a commercial catering group organized around three areas of activity: operation of owned restaurants: 108 restaurants operated under the theme restaurants names Hippopotamus, Bistro Romain and Taverne de Maître Kanter, and under the brewery brands Le Vaudeville, Bofinger, Terminus Norde and La Coupole; operation of restaurants underfranchise: 104 restaurants operated; operation of restaurants under concession: 12 restaurants operated (Disneyland Paris, Jardin des Plantes in Paris and CNIT at Paris La Défense). | $39.4M / Post-IPO Debt / Jul 01, 2020 | |
Dianosic
|
Dianosic was founded in 2017 and develops innovative solutions in the field of ENT (Ear, Nose & Throat), a $50 billion, double digit growth, and still largely underserved market. Our startup operates right at the frontier between Medtech and Biotech, as we see tremendous opportunities for drug-device combinations in this specialty. The projectoriginates from the ENT Department from the University Hospital of Strasbourg, where unmet clinical needs have been identified. Our main focus areas are Chronic Rhinitis, Chronic Sinusitis and intranasal bleeding (Epistaxis). Noteworthy, Dianosic has a strong French and German footprint in R&D and manufacturing.Dianosic’s strategic goal is to establish new standards of care in Chronic Rhinitis and Chronic Sinusitis with its drug-eluting Active Resorbable Scaffold (ARIS). This drug-device combination ARIS platform, developed with world renowned resorbable polymers experts, has the potential to establish new treatment paradigms. Moreover, our ARIS platform creates immense opportunities to create other verticals, especially in the field of chronic migraine and facial pain.Beside this, Dianosic commercialize an Asymmetric Intranasal inflatable solution (CAVI-T) for the treatment of intranasal bleeding, a widespread condition in ENT that affects 10% of the population. This CE marked and FDA registered technology addresses a clear unmet need and demonstrated our ability not only to develop a differentiated technology in record time, but also to successfully transition from R&D to Sales. We are currently present in relevant markets in EU and paving the way to launch in the U.S. in the mid term. Noteworthy, since our main call point is the ENT, CAVI-T prepares the ground for our upcoming ARIS platform. | $1.6M / Seed / Apr 14, 2020 |
Co-Investors
Bpifrance
3 deals together
BNP Paribas
2 deals together
Caisse d’Epargne
1 deal together
Nickleby Capital
1 deal together
Paris Business Angels
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Banque Populaire Rives de Paris invest in?
Banque Populaire Rives de Paris invests primarily in Laser, Beauty and Fitness startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Banque Populaire Rives de Paris's check size?
Banque Populaire Rives de Paris typically joins rounds of $1.6M–$1.6M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Banque Populaire Rives de Paris participates in.
How do I contact Banque Populaire Rives de Paris?
Public channels for Banque Populaire Rives de Paris include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Banque Populaire Rives de Paris?
The team at Banque Populaire Rives de Paris includes Arnaud Paquier (Corporate Business Center Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
